ReviewJournal of clinical medicine2026
Antithrombotic Therapy in Primary and Secondary Prevention of Coronary Artery Disease.
Review in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Antithrombotic Therapy in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antithrombotic therapy is central to the management of coronary artery disease (CAD), yet its optimal use requires a continuous balance between ischemic protection and bleeding risk. While aspirin has historically been the cornerstone of treatment, contemporary evidence supports a transition toward increasingly individualized strategies across the spectrum of disease. In primary prevention, the role of aspirin remains marginal and is limited to carefully selected high-risk individuals. Following percutaneous coronary intervention (PCI), dual antiplatelet therapy (DAPT) remains the standard of care; however, both its duration and composition are progressively tailored according to patient-specific ischemic and bleeding risk profiles. In chronic coronary syndromes, shorter DAPT followed by single antiplatelet therapy-particularly P2Y
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.